"Exploiting disease genomics to catalyse new medicines"
|
08:00 |
|
Registration |
|
08:30 |
|
Gavin Screaton, University of Oxford |
Welcome/Opening remarks |
|
|
|
|
|
|
Session 1: How do we select the best targets? |
|
|
|
Chair: Opher Gileadi |
|
08:45 |
|
Opher Gileadi, University of Oxford |
Introduction to the meeting |
09:00 |
|
Paul Workman, The Institute of Cancer Research |
Learning from Indiana Jones: Choose wisely in selecting targets and chemical probes |
09:30 |
|
Jenny Taylor, University of Oxford |
Using genomics to inform target selection |
09:55 |
|
Philippe Sanseau, Open Targets |
Selecting targets using Open Targets data |
10:20 |
|
Coffee and posters |
|
|
|
|
|
|
|
Session 2: Understanding disease mechanisms |
|
|
|
Chair: Wyatt Yue |
|
11:00 |
|
Steve O'Rahilly, University of Cambridge |
Understanding the causes and consequences of obesity |
11:30 |
|
David Collier, Eli Lilly |
New target discovery and qualification using genome-scale data |
11:55 |
|
Izabella Pena, The Children's Hospital of Eastern Ontario |
Targeting aminoadipate-semialdehyde synthase (AASS) for pyridoxine-dependent epilepsy (PDE) |
12:20 |
|
Liz Carpenter, University of Oxford |
A TEP for DPAGT1: from protein glycosylation diseases to antibiotic design |
12:45 |
|
Lunch and posters |
|
13:40 |
|
Lunchtime workshop |
Introduction to XChem - Anthony Bradley, University of Oxford |
|
|
|
|
|
|
Session 3: How do we enable early-stage drug discovery? |
|
|
|
Chair: Alex Bullock |
|
14:00 |
|
Joseph Newman, University of Oxford |
Targeting DNA repair pathways for cancer therapeutics : From structures to TEPs and beyond |
14:25 |
|
Jennifer Ward, University of Oxford |
Chemoproteomics as a tool in drug discovery |
14:50 |
|
Gregg Morin, University of British Columbia |
Proteogenomic characterization of CDK12 functions using a novel inhibitor |
15:15 |
|
Simon Ward, Cardiff University |
Neuropsychiatry - can we do better |
15:40 |
|
Coffee and posters |
|
|
|
|
|
|
|
Session 4: How do we address unmet clinical need? |
|
|
|
Chair: Liz Carpenter |
|
16:20 |
|
David Tapolczay, LifeArc |
How can the biomedical community in the UK exploit TEPs? |
16:45 |
|
Wen Hwa Lee, Structural Genomics Consortium |
We should all be I'MPATIENT - Open Science to accelerate discoveries with patient and disease foundations |
17:00 |
|
David Jenkinson, The Brain Tumour Charity |
Building partnerships to target a rare paediatric glioma |
17:15 |
|
Mike Ferguson, University of Dundee |
No substitute for activity! |
17:40 |
|
Chas Bountra, University of Oxford |
Closing remarks |